Young Joseph R 4

What Happened

• Joseph R. Young, Senior Vice President, Finance and Chief Accounting Officer of Vera Therapeutics (VERA), received equity awards on February 4, 2026: 10,000 restricted stock units (RSUs) and 20,000 derivative securities (an option award). Both awards were granted at $0.00 (i.e., no cash purchase price). These are compensation grants, not open-market purchases or sales.

Key Details

• Transaction date: 2026-02-04; Form 4 filed 2026-02-06 (timely — within the standard 2 business days).
• Awards: 10,000 RSUs (acquired at $0.00) and 20,000 derivative/share-equivalent award (acquired at $0.00).
• Post-transaction holdings: Not specified in the filing.
• Vesting / footnotes:
  • RSUs (10,000): Vest one-fourth on each of Feb 20, 2027, 2028, 2029 and 2030, subject to continuous service. (Footnote F1)
  • Derivative award (20,000): Vests 1/48th on March 4, 2026 and 1/48th monthly thereafter (subject to continuous service), per the filing (Footnote F2).
• Transaction code: A = Award/Grant.
• No indications of tax-withholding sale, 10b5-1 plan, or that shares were immediately sold.

Context

• These grants are routine equity compensation for an executive and do not represent an open-market buy or sell. Such awards are intended as long-term incentive/retention and vest over multiple years; they should not be read as a direct market-timing signal. The derivative award is an option-like grant with monthly vesting; RSUs convert to shares only as they vest.